Literature DB >> 26550161

Adenovirus expressing IFN-λ (Ad/hIFN-λ) produced anti-tumor effects through inducing apoptosis in human tongue squamous cell carcinoma cell.

Bing Song1, Yong Yang1, Yan-Li Wang2, Xiao-Hui Fan2, Yu-Mei Huang1, Hao-Su Ci1, Jin-Hua Zuo1.   

Abstract

OBJECTIVE: To investigate the potential therapeutic effects of adenovirus expressing IFN-λ1 and IFN-λ2 (Ad/hIFN-λ) in treating squamous cell carcinoma of the oral tongue (SCCOT) and to explore the underlying mechanisms.
METHODS: Two SCCOT cell lines HSC-3 and Tca8113 were adopted as study objects. Cell Counting Kit-8 (CCK-8) cell proliferation and viability assay was performed to evaluate the antiproliferative effects of Ad/hIFN-λ and IFN-λ treatments at different dosages. Flow cytometry (FCM) was performed to investigate the apoptosis rate induced by Ad/hIFN-λ. In vivo study was performed through evaluating tumorigenicity and tumor volume on BALB/c nu/nu mice inoculated with HSC-3 cells with or without infection of Ad/hIFN-λ. qPCR was used to screen important apoptosis related genes expression and western blot (WB) was performed to verify the results. WB was also used to test the phosphorylation of STATs protein in the JAK/STAT signaling pathways.
RESULTS: Our results indicated an obvious antiproliferative effect of Ad/hIFN-λ in vitro on infected HSC-3 and Tca8113 cells. The antiproliferative effects started to appear at 48 h (day 2) after infection. IFN-λs alone treating HSC-3 and Tca8113 cells also showed a dose-dependent inhibitory manner. Though the antiproliferative effects did not show on 24 h (day 1), early apoptosis rate already increased significantly in cells infected with Ad/hIFN-λ (P<0.05) detected by FCM. The underlying mechanisms of antiproliferative activity rely on the IFN-λ signaling by phosphorylation of STATs protein. Expression of Bax, Bcl-2 and Caspase-3 were promoted by Ad/hIFN-λ leading to higher apoptosis rate. Upper stream of p21 and Rb dephosphorylation explained the Caspase-3 activation. Animal study showed that HSC-3 cells infected with Ad/hIFN-λ significantly promoted the survival rate and decreased mean tumor volume comparing to HSC-3 cells group.
CONCLUSION: Ad/hIFN-λ injection had obvious antiproliferative effects on HSC-3 and Tca8113 cells. Ad/hIFN-λ induced apoptosis in SCCOT cells through increasing Bcl-2, Bax and Caspase-3 expression. Ad/hIFN-λ is a potential therapeutic strategy in treating oral tongue carcinoma.

Entities:  

Keywords:  Adenovirus; IFN-λ; JAK/STAT; apoptosis; oral tongue carcinoma

Year:  2015        PMID: 26550161      PMCID: PMC4612846     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  25 in total

1.  IL-28, IL-29 and their class II cytokine receptor IL-28R.

Authors:  Paul Sheppard; Wayne Kindsvogel; Wenfeng Xu; Katherine Henderson; Stacy Schlutsmeyer; Theodore E Whitmore; Rolf Kuestner; Ursula Garrigues; Carl Birks; Jenny Roraback; Craig Ostrander; Dennis Dong; Jinu Shin; Scott Presnell; Brian Fox; Betty Haldeman; Emily Cooper; David Taft; Teresa Gilbert; Francis J Grant; Monica Tackett; William Krivan; Gary McKnight; Chris Clegg; Don Foster; Kevin M Klucher
Journal:  Nat Immunol       Date:  2002-12-02       Impact factor: 25.606

2.  Regulation of apoptosis by type III interferons.

Authors:  W Li; A Lewis-Antes; J Huang; M Balan; S V Kotenko
Journal:  Cell Prolif       Date:  2008-12       Impact factor: 6.831

3.  IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex.

Authors:  Sergei V Kotenko; Grant Gallagher; Vitaliy V Baurin; Anita Lewis-Antes; Meiling Shen; Nital K Shah; Jerome A Langer; Faruk Sheikh; Harold Dickensheets; Raymond P Donnelly
Journal:  Nat Immunol       Date:  2002-12-16       Impact factor: 25.606

4.  Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer.

Authors:  Phonphimon Wongthida; Rosa Maria Diaz; Feorillo Galivo; Timothy Kottke; Jill Thompson; Jose Pulido; Kevin Pavelko; Larry Pease; Alan Melcher; Richard Vile
Journal:  Cancer Res       Date:  2010-05-18       Impact factor: 12.701

5.  Adenovirus expressing IFN-λ1 (IL-29) attenuates allergic airway inflammation and airway hyperreactivity in experimental asthma.

Authors:  Yan Li; Qiaoyan Gao; Xianli Yuan; Mi Zhou; Xiao Peng; Xiaojin Liu; Xiaoxuan Zheng; Damo Xu; Mingcai Li
Journal:  Int Immunopharmacol       Date:  2014-05-09       Impact factor: 4.932

6.  IFN-λ-mediated IL-12 production in macrophages induces IFN-γ production in human NK cells.

Authors:  Rik A de Groen; Arjan Boltjes; Jun Hou; Bi-Sheng Liu; Fiona McPhee; Jacques Friborg; Harry L A Janssen; André Boonstra
Journal:  Eur J Immunol       Date:  2014-11-10       Impact factor: 5.532

Review 7.  Interferons: mechanisms of action and clinical applications.

Authors:  Simrit Parmar; Leonidas C Platanias
Journal:  Curr Opin Oncol       Date:  2003-11       Impact factor: 3.645

8.  Inhibition of lung adenocarcinoma transfected with interleukin 28A recombinant adenovirus (Ad-mIFN-λ2) in vivo.

Authors:  Yulan Yan; Jin Zhang; Yang Liu; Taofeng Zhu; Lixue Yuan; Yuxi Ge; Hao Ding; Xuefeng Bu
Journal:  Cancer Biother Radiopharm       Date:  2012-11-07       Impact factor: 3.099

Review 9.  Interferon lambda: a new sword in cancer immunotherapy.

Authors:  Ahmed Lasfar; Walid Abushahba; Murugabaskar Balan; Karine A Cohen-Solal
Journal:  Clin Dev Immunol       Date:  2011-12-06

10.  MDSCs mediate angiogenesis and predispose canine mammary tumor cells for metastasis via IL-28/IL-28RA (IFN-λ) signaling.

Authors:  Joanna Mucha; Kinga Majchrzak; Bartłomiej Taciak; Eva Hellmén; Magdalena Król
Journal:  PLoS One       Date:  2014-07-30       Impact factor: 3.240

View more
  1 in total

1.  Mesenchymal stem cell-derived interleukin-28 drives the selection of apoptosis resistant bone metastatic prostate cancer.

Authors:  Jeremy J McGuire; Jeremy S Frieling; Chen Hao Lo; Tao Li; Ayaz Muhammad; Harshani R Lawrence; Nicholas J Lawrence; Leah M Cook; Conor C Lynch
Journal:  Nat Commun       Date:  2021-02-01       Impact factor: 17.694

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.